Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Perspective Therapeutics, Inc.

CATX

Perspective Therapeutics Inc is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties.

Last trade $0.8589
Day change -$0.0649 (-7.03%)
Day range $0.812 – $0.974
Volume 1,929,336
Market cap $112M

Open XASE

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$111.1M
Price / earnings
—
Price / book
0.38×
Price / sales
504.99×
EV / sales
325.63×
EV / EBITDA
-0.56×

Profitability

Earnings per share
-$1.02
Return on assets
-33.61%
Return on equity
-41.71%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0.01×
Current ratio
5.18×
Quick ratio
5.18×
Cash ratio
1.04×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$138.84M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for CATX, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$20K$81K$76K$43K$209K$290K$342K$234K
Cost of revenue$0$0$0$0$0$0$0$0
Gross profit$20K$81K$76K$43K$209K$290K$342K$234K
Selling, general and administrative$8.27M$7.8M$6.99M$6.95M$7.73M$7.71M$7.84M$8.25M
Research and development$26.07M$21.54M$21.37M$32.92M$20.34M$16.62M$14.33M$12.88M
Total operating expenses$34.34M$29.34M$28.36M$39.88M$28.07M$24.33M$22.17M$45.19M
Operating income-$34.32M-$29.26M-$28.28M-$39.83M-$27.86M-$24.04M-$21.83M-$44.96M
Interest expense-$157K-$71K-$105K-$64K-$65K-$119K-$128K$73K
Income before taxes-$32.44M-$26.98M-$26.19M-$38.28M-$25.97M-$22M-$18.18M-$42.27M
Income taxes$0$0$0-$793K$0$0$0-$2.1M
Net income-$32.44M-$26.79M-$26.19M-$37.49M-$25.97M-$21.49M-$18.18M-$40.17M
Net income attributable to common shareholders-$32.44M-$26.79M-$26.19M-$37.49M-$25.97M-$21.49M-$18.18M-$40.17M
EBITDA-$33.13M-$28.12M-$27.16M-$38.82M-$27.09M-$23.31M-$21.1M-$20.19M
Basic earnings per share-$0.27-$0.22-$0.25-$0.50-$0.35-$0.29-$0.25-$0.57
Diluted earnings per share-$0.27-$0.22-$0.25-$0.50-$0.35-$0.29-$0.25-$0.57

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

Perspective Therapeutics Presents Encouraging Incremental Data and Analyses from Phase 1/2a Trial of [212Pb]Bamzireotide Navoxetan (VMT-α-NET) in Advanced SSTR2 Expressing NETs

Perspective Therapeutics announced positive Phase 1/2a trial data for bamzireotide navoxetan (VMT-α-NET) in neuroendocrine tumor patients. The drug demonstrated durable disease control with 75% progression-free survival at 18 months in GEP-NET patients with SSTR2-positive target lesions, compared to 65% for an approved competitor. The treatment was well-tolerated with no dose-limiting toxicities or treatment discontinuations. The company plans an end-of-Phase 2 meeting with the FDA in Q1 2027 and aims to initiate Phase 3 studies in 2027.

Zacks Investment Research

Strength Seen in Profound Medical (PROF): Can Its 21.7% Jump Turn into More Strength?

Profound Medical (PROF) surged 21.7% following strong preliminary Q3 2026 revenue guidance of $9.8-10 million, representing 85-89% year-over-year growth and 45-47% above analyst consensus. The company expects gross margins exceeding 70%, signaling improved commercial momentum. However, with unchanged earnings estimate revisions over the past 30 days, analysts caution that the stock's momentum may not sustain without further positive estimate revisions.

GlobeNewswire Inc.

Perspective Therapeutics to Present Data from All Clinical Programs at the 2026 ASCO Annual Meeting, including Findings from [212Pb]VMT01 in Melanoma

Perspective Therapeutics announced it will present updated clinical data from all three of its radiopharmaceutical programs at the 2026 ASCO Annual Meeting. Key highlights include one new responder in the [212Pb]VMT01 melanoma monotherapy cohort (29% response rate), advancement of [212Pb]PSV359 to Cohort 3 with favorable safety profile, and continued deepening of responses in [212Pb]VMT-α-NET for neuroendocrine tumors. All programs demonstrated good tolerability with no dose-limiting toxicities reported.

GlobeNewswire Inc.

Pheochromocytoma and Paraganglioma Market to Exhibit Growth at 7.3% CAGR by 2036 Driven by the Advent of Drug Classes Such as SSTR2 analogs, Dopamine Receptor D2 Agonists, TAAs or TSAs, and Others | DelveInsight

The pheochromocytoma and paraganglioma (PCPG) market is projected to grow at 7.3% CAGR through 2036, driven by emerging therapies including radioligand treatments, HIF-2α inhibitors, and targeted agents. The market was valued at USD 300 million in 2025 across seven major markets, with the US accounting for 67% of the market. Key companies including Novartis, Jazz Pharmaceuticals, Perspective Therapeutics, and Merck are advancing innovative treatments, with WELIREG (belzutifan) expected to generate the highest revenue by 2036.

GlobeNewswire Inc.

Perspective Therapeutics Presents Updated Interim Data of [212Pb]VMT-α-NET in Its Ongoing Phase 1/2a Clinical Trial at the 2026 AACR Annual Meeting

Perspective Therapeutics announced updated interim results from its Phase 1/2a clinical trial of [212Pb]VMT-α-NET, a first-in-class 212Pb-radiopharmaceutical targeting SSTR2-positive neuroendocrine tumors. The trial showed a 43% objective response rate in Cohort 2 patients, with no dose-limiting toxicities or serious treatment-related complications. The company plans to submit clinical evidence for regulatory engagement in 2026.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Jun 17, 20241-for-10reverse split